Sofinnova Announces the Addition of Industry Leader Alan Colowick, MD, MPH to its Partnership

Dr. Colowick has 18 years of industry experience in senior executive, clinical, regulatory, and commercial functions. Prior to joining Sofinnova, Alan was an Executive Vice President at Celgene Corporation and served in various leadership roles including President for Celgene's Europe, Mid-East, and Africa regions and before that, Senior Vice President of Global Medical Affairs. Prior to his career at Celgene, Alan was the Chief Executive Officer at Gloucester Pharmaceuticals, Inc. until its acquisition by Celgene in 2010. Alan also served as the President of Oncology at Geron Corporation, and before that, he served as the Chief Medical Officer of Threshold Pharmaceuticals, a Sofinnova portfolio company.  Alan has held numerous positions of increasing responsibility at Amgen culminating with his role as VP, Medical Affairs Europe. He currently serves on the Board of Directors for Achaogen, Inc, Dimension Therapeutics Inc., Principia Biopharma and Human Longevity, Inc.

Alan received an M.D. from Stanford University and an M.P.H from Harvard University. He completed specialty training in Hematology-Oncology at the Dana Farber Cancer Institute and Brigham and Women's Hospital. Alan has a B.S. in Molecular Biology from the University of Colorado.

"Sofinnova has had the pleasure of working with Alan dating back to his time as the Chief Medical Officer at Threshold," says Jim Healy, MD, PhD and General Partner. "We have always had such tremendous respect for Alan.  His breadth of experience spans large pharma and emerging biotech companies.  We believe he is going to add incredible value to our team and our portfolio companies."

"In my view, Sofinnova has a terrific track record of creating and building companies that have benefited patients by focusing on robust science and therapeutic areas with high unmet medical needs," comments Dr. Colowick "I am thrilled to join Sofinnova and look forward to being part of the team as we build on this legacy."

Sofinnova closed its tenth venture fund in 2016, raising $650 million.  Sofinnova is managed by experienced venture capitalists and industry executives. The team takes a focused, hands-on approach to drug development and company building. 

The partners of SVP X are Jim Healy, MD, PhD, Anand Mehra, MD, Mike Powell, PhD, Alan Colowick, MD, MPH, Lars Ekman, MD, PhD, David Kabakoff, PhD and Dan Welch.

About Sofinnova

Founded in 1974, Sofinnova specializes in clinical and late preclinical investments in biopharmaceutical products. Our goal is to actively partner with entrepreneurs across all stages of company development. We seek to build world class companies that aspire to dramatically improve the current state of medical care and the lives of patients through bringing innovative products to market. For more information, please visit www.sofinnova.com

Contact:
Charlotte Shropshire
[email protected]

SOURCE Sofinnova

Related Links

http://www.sofinnova.com